Akebia, chasing FibroGen, nears FDA review with new anemia pill data

The company is one of several aiming to upend the market for injectable anemia biologics, which generate billions of dollars in yearly sales.

Akebia, chasing FibroGen, nears FDA review with new anemia pill data
The company is one of several aiming to upend the market for injectable anemia biologics, which generate billions of dollars in yearly sales.